JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / VECTOR &VIRUS / Lentivirus

Dominant Negative TGF-beta Receptor Type II (TGF-betaRII) Lentivirus

SKU : BHV18200011

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	78928
Description	Dominant Negative TGF-β Receptor Type II (TGF-βRII) Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human dominant negative TGF-βRII, missing the intracellular kinase domain (NM_003242.6; amino acid 1-191), driven by an EF1a promoter and a puromycin selection marker. Transforming growth factor receptor beta 2 (TGFBR2), or TGFβRII, encodes the TGFβ receptor serine/threonine kinase, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGFβ. The association of TGFβ with TGFβRII leads to the phosphorylation of proteins, such as SMADs, involved in cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Dysfunction of the TFGβ signaling tends to result in cancer development and progression. In the case of solid tumors, TGFβ signaling plays a role in creating a highly immunosuppressive TME (tumor microenvironment), restricting the efficacy of CAR (chimeric receptor antigen)- T cells, which have proved successful in the treatment of hematological cancers. Recently, the use of CAR-T cells armored with a dominant negative form of TGFβRII, missing the intracellular kinase domain, for the treatment of prostate cancer resulted in promising outcomes. 5 out of 13 patients did suffer cytokine release syndrome, which continues to be a concern with CAR-T applications, but on the whole the use of a dominant negative TGFβ receptor to armor CAR-T cells appears to be an approach that deserves further attention in the cancer therapy field. The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee. Biosafety The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Applications Range	Expression of human dominant negative TGF-βRII in cells of interest. Generate cell pools or stable cell lines expressing human TGF-βRII following puromycin selection.
Storage	Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Shipping	-80°C

Reference Paper	Ikushima H. and Miyazono K., 2010 Nature Reviews Cancer 10:415-424. Narayan V., et al., 2022 Nat Med 28:724-34.

Expression of dominant negative TGF-βRII in CHO cells transduced with Dominant Negative TGF-β Receptor Type II (TGF-βRII) Lentivirus

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHV18200011	78928	500 µl x 2	$1250		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.